Edition:
United Kingdom

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
184,583
52-wk High
$2.14
52-wk Low
$0.39

Latest Key Developments (Source: Significant Developments)

Contravir expands scientific advisory board for Hepatitis B
Monday, 18 Jul 2016 

Contravir Pharmaceuticals : Carol L. Brosgart appointed chair of SAB in support of Contravir's development of a potentially curative therapy for hbv .Contravir expands scientific advisory board to focus on seeking curative therapy for Hepatitis B.  Full Article

Contravir says doses first patients in head-to-head study of CMX157 vs Viread
Tuesday, 21 Jun 2016 

Contravir : Doses first patients in head-to-head study of Cmx157 versus. Viread® for treating hepatitis b . Study is expected to conclude in q4 of 2016 .Phase 1b study in line with expectations into final 100 mg dosing group.  Full Article

Contravir Pharma initiates mid-stage study of CMX157 for treating hepatitis B
Wednesday, 1 Jun 2016 

Contravir Pharmaceuticals Inc : Contravir initiates head-to-head phase 2a clinical study of cmx157 versus. viread® for treating hepatitis b .Contravir pharmaceuticals inc says final results from this study are expected in q4 of 2016.  Full Article

Contravir to expand hepatitis B portfolio
Tuesday, 31 May 2016 

Contravir Pharmaceuticals Inc : Contravir to expand hepatitis B portfolio through strategic merger agreement with ciclofilin pharmaceuticals . Milestone payments will consist of up to an aggregate $17 million cash and up to 10% of Contravir's issued and outstanding common stock . Merger has been approved by board of directors of both companies . Following completion of transaction, ciclofilin will become a wholly owned subsidiary of contravir. . Contravir to expand hepatitis b portfolio through strategic merger agreement with ciclofilin pharmaceuticals .To quire outstanding equity interests in ciclofilin to receive future milestone payments to be allocated among holders of ciclofilin stock.  Full Article

ContraVir Pharmaceuticals Inc announces proposed public offering of common stock
Tuesday, 29 Mar 2016 

ContraVir Pharmaceuticals Inc:Intends to offer shares of its common stock and warrants to purchase shares of its common stock in a "best efforts" underwritten public offering.  Full Article

BRIEF-Contravir Pharmaceuticals enters research collaboration with Li Ka Shing Institute of Virology

* Contravir Pharmaceuticals announces research collaboration agreement with Li Ka Shing Institute of Virology Source text for Eikon: Further company coverage: (Reporting by Sruthi Ramakrishnan)